| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802395401022 | 239540102 | TRAMAL CAPS 50MG/CAP BTx30 (BLISTER 3x10) | 2.22 | 2.33 | 3.21 |
| 05/2018 | 2802395402012 | 239540201 | TRAMAL OR.SO.D 100MG/ML FL x 10 ML | 2.43 | 2.55 | 3.52 |
| 05/2018 | 2802395403026 | 239540302 | TRAMAL SUPP 100MG/SUP BT x 10(2 FOIST x 5) | 02.04 | 2.14 | 2.95 |
| 05/2018 | 2802395404016 | 239540401 | TRAMAL INJ.SOL 100MG/2ML AMP BT x 5 AMPS x 2 ML | 02.09 | 2.19 | 03.02 |
| 05/2018 | 2802395405099 | 239540509 | TRAMAL SR PR.TAB 50MG/TAB BTx60 (BLISTER 6x10) Aluminium/Polypropylene | 3.79 | 3.98 | 5.48 |
| 05/2018 | 2802395406096 | 239540609 | TRAMAL SR PR.TAB 100MG/TAB BTx60 (BLISTER 6x10) Aluminium/Polypropylene | 6.10 | 6.40 | 8.82 |
| 05/2018 | 2802395407031 | 239540703 | TRAMAL SR PR.TAB 150MG/TAB BTx30 (BLISTER 3x10) Aluminium/Polypropylene | 3.38 | 3.55 | 4.90 |
Indicated in the treatment of moderate to severe pain. Consider for those prone to constipation or respiratory depression. Tramadol is used to treat postoperative, dental, cancer, and acute musculosketetal pain and as an adjuvant to NSAID therapy in patients with osteoarthritis.
Tramadol and its O-desmethyl metabolite (M1) are selective, weak OP3-receptor agonists. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. The analgesic properties of Tramadol can be attributed to norepinephrine and serotonin reuptake blockade in the CNS, which inhibits pain transmission in the spinal cord. The (+) enantiomer has higher affinity for the OP3 receptor and preferentially inhibits serotonin uptake and enhances serotonin release. The (-) enantiomer preferentially inhibits norepinephrine reuptake by stimulating alpha(2)-adrenergic receptors.
LD<sub>50</sub>=350mg/kg (orally in mice)
Racemic tramadol is rapidly and almost completely absorbed after oral administration. The mean absolute bioavailability of a 100 mg oral dose is approximately 75%.The mean peak plasma concentration of racemic tramadol and M1 occurs at two and three hours, respectively, after administration in healthy adults.
23 +/- 10 minutes
Tramadol is eliminated primarily through metabolism by the liver and the metabolites are eliminated primarily by the kidneys. Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites.
* 2.6 L/kg [male 100 mg intravenous dose] * 2.9 L/kg [female 100 mg intravenous dose]
* 5.9 mL/min/Kg [Healthy Adults, 100 mg qid, MD p.o] * 8.5 mL/min/Kg [Healthy Adults, 100 mg SD p.o] * 6.89 mL/min/Kg [Geriatric, (<75 yr), 50 mg SD p.o.] * 4.23 mL/min/Kg [Hepatic Impaired, 50 mg SD p.o.] * 4.23 mL/min/Kg [Renal Impaired, Clcr10-3mL/min, 100 mg SD i.v.] * 3.73 mL/min/Kg [Renal Impaired, CLcr<5 mL/min, 100 mg SD i.v.] * 6.4 mL/min/Kg [Male following a 100 mg IV dose] * 5.7 mL/min/Kg [Female following a 100 mg IV dose]